Clinical Trials Logo

Ocular Hypertension clinical trials

View clinical trials related to Ocular Hypertension.

Filter by:

NCT ID: NCT01318252 Completed - Clinical trials for Ocular Hypertension (OHT)

AL-54478 Proof of Concept Study

Start date: June 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of AL-54478 0.005% compared with Latanoprost 0.005% and AL-54478 Vehicle in patients with open-angle glaucoma or ocular hypertension.

NCT ID: NCT01310777 Completed - Ocular Hypertension Clinical Trials

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

Start date: May 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the safety and efficacy of Brinzolamide/Brimonidine in lowering intraocular pressure (IOP) relative to each of its individual active components in patients with open-angle glaucoma or ocular hypertension.

NCT ID: NCT01309204 Completed - Ocular Hypertension Clinical Trials

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

Start date: May 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the safety and efficacy of Brinzolamide/Brimonidine fixed combination in lowering intraocular pressure (IOP) relative to each of its individual active constituents instilled concomitantly (Brinzolamide+Brimonidine) in patients with open-angle glaucoma or ocular hypertension.

NCT ID: NCT01306461 Completed - Ocular Hypertension Clinical Trials

Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations

Start date: March 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost and timolol (FDC) to concomitant administration of tafluprost and timolol. This study will enroll patients who have ocular hypertension or glaucoma. The study schedule includes seven visits to the study site and three stages: - washout of 5 days to 4 weeks depending on current glaucoma medication (if any) - 6-month study treatment period - 1-3 weeks post-study period

NCT ID: NCT01302249 Completed - Glaucoma Clinical Trials

AR-12286 in Combination With Latanoprost

Start date: February 2011
Phase: Phase 2
Study type: Interventional

This is a double-masked, randomized, multi-center, active-controlled, crossover comparison of the addition of AR-12286 or timolol to latanoprost in the treatment of elevated intraocular pressure (IOP).

NCT ID: NCT01298700 Completed - Glaucoma Clinical Trials

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Start date: May 31, 2011
Phase: Phase 4
Study type: Interventional

This study will evaluate the long-term safety of bimatoprost 0.01% ophthalmic solution compared with bimatoprost 0.03% ophthalmic solution in patients with glaucoma or ocular hypertension.

NCT ID: NCT01298687 Completed - Ocular Hypertension Clinical Trials

Divided Dose of TRAVATAN®

Start date: February 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the incremental dosing of travoprost ophthalmic solution versus once a day dosing of TRAVATAN® in lowering intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

NCT ID: NCT01297920 Completed - Ocular Hypertension Clinical Trials

Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%

Start date: March 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the safety and efficacy of a new ophthalmic suspension (Brinz/Brim) in lowering intraocular pressure (IOP) relative to its individual active components in subjects with open-angle glaucoma and/or ocular hypertension.

NCT ID: NCT01297517 Completed - Ocular Hypertension Clinical Trials

Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%

Start date: February 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of a fixed combination of Brinzolamide/Brimonidine in lowering intraocular pressure (IOP) relative to each of its individual active components in patients with open-angle glaucoma and/or ocular hypertension.

NCT ID: NCT01292460 Completed - Ocular Hypertension Clinical Trials

Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies

Start date: February 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of the preservative-free fixed tafluprost-timolol combination to those of tafluprost and timolol alone. This study will enroll patients who have ocular hypertension or glaucoma and who are using timolol or prostaglandin. The study medication period is 6 months, but the primary evaluation of efficacy is done at 3 months.